Positive News SentimentPositive NewsNASDAQ:CTXR Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis $1.33 -0.07 (-5.00%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.33 0.00 (-0.30%) As of 08/29/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Citius Pharmaceuticals Stock (NASDAQ:CTXR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Citius Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.31▼$1.5750-Day Range$1.03▼$2.2052-Week Range$0.65▼$15.25Volume2.36 million shsAverage Volume341,734 shsMarket Capitalization$22.62 millionP/E RatioN/ADividend YieldN/APrice Target$53.00Consensus RatingModerate Buy Company Overview Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey. Read More Citius Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCTXR MarketRank™: Citius Pharmaceuticals scored higher than 61% of companies evaluated by MarketBeat, and ranked 488th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCitius Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCitius Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Citius Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($4.50) to $1.25 per share.Price to Book Value per Share RatioCitius Pharmaceuticals has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.31% of the float of Citius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCitius Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Citius Pharmaceuticals has recently decreased by 31.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCitius Pharmaceuticals does not currently pay a dividend.Dividend GrowthCitius Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.31% of the float of Citius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCitius Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Citius Pharmaceuticals has recently decreased by 31.31%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentCitius Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Citius Pharmaceuticals this week, compared to 1 article on an average week.Search Interest22 people have searched for CTXR on MarketBeat in the last 30 days. This is an increase of 633% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.88% of the stock of Citius Pharmaceuticals is held by institutions.Read more about Citius Pharmaceuticals' insider trading history. Receive CTXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTXR Stock News HeadlinesCitius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR LaunchAugust 22, 2025 | prnewswire.comCitius Posts Wider Loss in Fiscal Q3August 14, 2025 | theglobeandmail.comCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.August 31 at 2:00 AM | Timothy Sykes (Ad)Citius Pharmaceuticals reports Q3 EPS (8c) vs.(7c) last yearAugust 12, 2025 | msn.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides ...August 12, 2025 | gurufocus.comCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | prnewswire.comCitius Oncology Announces Closing of $9.0 Million Public OfferingJuly 17, 2025 | prnewswire.comCitius Oncology Announces Pricing of $9.0 Million Public OfferingJuly 16, 2025 | prnewswire.comSee More Headlines CTXR Stock Analysis - Frequently Asked Questions How have CTXR shares performed this year? Citius Pharmaceuticals' stock was trading at $4.00 at the beginning of the year. Since then, CTXR stock has decreased by 66.8% and is now trading at $1.33. How were Citius Pharmaceuticals' earnings last quarter? Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) issued its earnings results on Tuesday, August, 12th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.04. The business had revenue of $1.92 million for the quarter, compared to analysts' expectations of $1.92 million. When did Citius Pharmaceuticals' stock split? Citius Pharmaceuticals's stock reverse split before market open on Tuesday, November 26th 2024.The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Citius Pharmaceuticals' major shareholders? Top institutional shareholders of Citius Pharmaceuticals include Geode Capital Management LLC (0.72%), NewEdge Advisors LLC (0.24%), XTX Topco Ltd (0.19%) and Arkadios Wealth Advisors (0.19%). View institutional ownership trends. How do I buy shares of Citius Pharmaceuticals? Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/12/2025Today8/31/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTXR CIK1506251 Webwww.citiuspharma.com Phone(908) 967-6677FaxN/AEmployees20Year Founded2007Price Target and Rating Average Price Target for Citius Pharmaceuticals$53.00 High Price Target$100.00 Low Price Target$6.00 Potential Upside/Downside+3,885.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.14 million Net MarginsN/A Pretax MarginN/A Return on Equity-60.03% Return on Assets-33.83% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.34Miscellaneous Outstanding Shares17,010,000Free Float15,192,000Market Cap$22.62 million OptionableOptionable Beta1.19 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CTXR) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.